556P - Pathological characteristics according to age at diagnosis in 2929 men with prostate cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Prostate Cancer
Pathology/Molecular Biology
Presenter Gang Song
Citation Annals of Oncology (2016) 27 (suppl_9): ix181-ix183. 10.1093/annonc/mdw602
Authors G. Song
  • Urology, Peking University First Hospital, 100034 - Beijing/CN

Abstract

Background

This study aimed to compare pathological characteristics according to age at diagnosis in men with prostate cancer.

Methods

A single institution review of 2,929 records of patients diagnosed with prosate cancer from Jan 2000-Jun 2016 was conducted. Patients were stratified by age group: ≤55 years old (Group 1, young men), 55 years old -75 years old (Group 2, middle aged-older men), >75 years old (Group 3, very old men). The pathological characteristics (Gleason sum, primary Gleason score, the second primary Gleason score, the percent of Gleason pattern 5) was compared between the three groups.

Results

Only 4.5% (133 cases) of the study sample was ≤55 years of age. There were 2033 cases (69.5%), 763 cases (26.0%) in the group 2 and 3. The median Gleason sum were 8 (6-10), 7 (3-10), 8 (3-10), respectively. Gleason sum, primary Gleason score, the second primary Gleason scores were different between the three groups (X2=12.975, P=0.002; X2=9.264, P=0.010; X2=6.692, P=0.035). The percent of Gleason pattern 5 were 44.4%, 32.3%, 36.8%, with significant differences (X2=11.641, P=0.003) between the three groups. The differences between Group 1 & 2 or Group 2 & 3 were also significant (X2=8.183, P=0.004; X2=5.065, P=0.024).

Conclusions

The Gleason sums are different according to age. The percent of Gleason pattern 5 in men≤55 years old orin men >75 years old are much higher than that in men 55 years old-75 years old. The prostate cancer are more aggressive in young or very older men than in middle aged-older men.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

Capital Clinical Research Project

Disclosure

All authors have declared no conflicts of interest.